Roivant fixed the accounts payable exception problem by cleaning matching logic, restructuring PO reconciliation, and setting tolerances deliberately instead of by accident.
Published
Signal category
Technology & Infrastructure
Quote
“So we fixed the plumbing. Cleaned the matching logic. Restructured how POs were built so they'd actually reconcile against what came in. Set the tolerances deliberately instead of by accident.”
— Mavelyn Cuches, MBA|Roivant team
Company
- Industry
- Biotechnology
- Location
- New York, US
- Company size
- 227 employees
Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology. The therapies in development across our family of companies target a wide range of diseases including uterine fibroids, endometriosis, prostate cancer, Parkinson’s disease, diabetes, pulmonary arterial hypertension, and multiple rare and fatal pediatric conditions. We focus on disease areas where the magnitude of R&D investment from industry is disproportionately low relative to societal medical needs. In addition to our biopharmaceutical subsidiaries, we also build technology-focused Vants focused on improving the process of developing and commercializing medicines.